Intelligence / Healthtech / New Clinical Trials / Sichuan Credit Pharmaceutical Co., Ltd.
Sichuan Credit Pharmaceutical Co., Ltd.
23 Oct 2026: Trial registered · A Randomized, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 23 Oct 2026
- Title
- A Randomized, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study
- Conditions
- Adjunct in the Treatment of Depressive Disorder
- Phase
- Not applicable
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- India
- Country
- India
- Reference
- NCT07893002
- Location
- India
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Sichuan Credit Pharmaceutical Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from India
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.